{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:22:08Z","timestamp":1787977328059,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372470"],"award-info":[{"award-number":["81372470"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00262-022-03209-1","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T03:37:41Z","timestamp":1652326661000},"page":"2969-2983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy"],"prefix":"10.1007","volume":"71","author":[{"given":"Xu-Dong","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui-Lin","family":"L\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Jian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Qiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-8603","authenticated-orcid":false,"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"issue":"6024","key":"3209_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331(6024):1565\u20131570","journal-title":"Science"},{"key":"3209_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235\u2013271","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"3209_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1158\/2326-6066.CIR-14-0110","volume":"2","author":"OJ Finn","year":"2014","unstructured":"Finn OJ (2014) Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res 2(8):708\u2013713","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"3209_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14(2):135\u2013146","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3209_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nbt.2725","volume":"31","author":"CS Hinrichs","year":"2013","unstructured":"Hinrichs CS, Restifo NP (2013) Reassessing target antigens for adoptive T-cell therapy. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 31(11):999\u20131008","journal-title":"Nat Biotechnol"},{"issue":"3","key":"3209_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00262-004-0560-6","volume":"54","author":"L Novellino","year":"2005","unstructured":"Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54(3):187\u2013207","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"3209_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/cas.12650","volume":"106","author":"Y Nishimura","year":"2015","unstructured":"Nishimura Y, Tomita Y, Yuno A, Yoshitake Y, Shinohara M (2015) Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. Cancer Sci 106(5):505\u2013511","journal-title":"Cancer Sci"},{"key":"3209_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fonc.2014.00195","volume":"4","author":"E Hammond","year":"2014","unstructured":"Hammond E, Khurana A, Shridhar V, Dredge K (2014) The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol 4:195","journal-title":"Front Oncol"},{"issue":"19","key":"3209_CR9","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1111\/j.1742-4658.2010.07799.x","volume":"277","author":"U Barash","year":"2010","unstructured":"Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277(19):3890\u20133903","journal-title":"FEBS J"},{"issue":"6","key":"3209_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4155\/fmc-2016-0012","volume":"8","author":"S Rivara","year":"2016","unstructured":"Rivara S, Milazzo FM, Giannini G (2016) Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem 8(6):647\u2013680","journal-title":"Future Med Chem"},{"issue":"3","key":"3209_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2174\/1568009614666140224155124","volume":"14","author":"V Masola","year":"2014","unstructured":"Masola V, Secchi MF, Gambaro G, Onisto M (2014) Heparanase as a target in cancer therapy. Curr Cancer Drug Targets 14(3):286\u2013293","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"3209_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bcp.2014.02.010","volume":"89","author":"C Pisano","year":"2014","unstructured":"Pisano C, Vlodavsky I, Ilan N, Zunino F (2014) The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol 89(1):12\u201319","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"3209_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12307-011-0082-7","volume":"5","author":"I Vlodavsky","year":"2012","unstructured":"Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N, Elkin M (2012) Significance of heparanase in cancer and inflammation. Cancer Microenviron 5(2):115\u2013132","journal-title":"Cancer Microenviron"},{"issue":"5","key":"3209_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1158\/0008-5472.CAN-07-5965","volume":"68","author":"XD Tang","year":"2008","unstructured":"Tang XD, Wan Y, Chen L, Chen T, Yu ST, Xiong Z, Fang DC, Liang GP, Yang SM (2008) H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo. Cancer Res 68(5):1529\u20131537","journal-title":"Cancer Res"},{"issue":"5","key":"3209_CR15","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1158\/1535-7163.MCT-11-0607","volume":"11","author":"XD Tang","year":"2012","unstructured":"Tang XD, Wang GZ, Guo J, L\u00fc MH, Li C, Li N, Chao YL, Li CZ, Wu YY, Hu CJ, Fang DC, Yang SM (2012) Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo. Mol Cancer Ther 11(5):1183\u20131192","journal-title":"Mol Cancer Ther"},{"key":"3209_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev.iy.11.040193.001241","volume":"11","author":"HG Rammensee","year":"1993","unstructured":"Rammensee HG, Falk K, R\u00f6tzschke O (1993) Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11:213\u2013244","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"3209_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1593\/neo.08576","volume":"10","author":"T Chen","year":"2008","unstructured":"Chen T, Tang XD, Wan Y, Chen L, Yu ST, Xiong Z, Fang DC, Liang GP, Yang SM (2008) HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia 10(9):977\u2013986","journal-title":"Neoplasia"},{"issue":"7","key":"3209_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00262-010-0829-x","volume":"59","author":"XD Tang","year":"2010","unstructured":"Tang XD, Liang GP, Li C, Wan Y, Chen T, Chen L, Yu ST, Xiong Z, Fang DC, Wang GZ, Yang SM (2010) Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice. Cancer Immunol Immunother 59(7):1041\u20131047","journal-title":"Cancer Immunol Immunother"},{"key":"3209_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/B978-0-12-396548-6.00006-8","volume":"114","author":"HY Wang","year":"2012","unstructured":"Wang HY, Wang RF (2012) Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv Immunol 114:151\u2013176","journal-title":"Adv Immunol"},{"issue":"1","key":"3209_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cr.2016.155","volume":"27","author":"RF Wang","year":"2017","unstructured":"Wang RF, Wang HY (2017) Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res 27(1):11\u201337","journal-title":"Cell Res"},{"issue":"10","key":"3209_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, Ahrends T, B\u0105ba\u0142a N, Melief CJM, Kastenm\u00fcller W (2018) CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18(10):635\u2013647","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"3209_CR22","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00262-017-2029-4","volume":"66","author":"T L\u00f6vgren","year":"2017","unstructured":"L\u00f6vgren T, Sarhan D, Truxov\u00e1 I et al (2017) Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-\u03b3 and multiple toll-like receptor agonists. Cancer Immunol Immunother 66(10):1333\u20131344","journal-title":"Cancer Immunol Immunother"},{"key":"3209_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1746-6148-10-2","volume":"10","author":"CX Zhou","year":"2014","unstructured":"Zhou CX, Li D, Chen YL et al (2014) Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine. BMC Vet Res 10:2","journal-title":"BMC Vet Res"},{"key":"3209_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jconrel.2015.09.062","volume":"219","author":"CH Kapadia","year":"2015","unstructured":"Kapadia CH, Perry JL, Tian S, Luft JC, DeSimone JM (2015) Nanoparticulate immunotherapy for cancer. J Control Release 219:167\u2013180","journal-title":"J Control Release"},{"issue":"5","key":"3209_CR25","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","volume":"14","author":"K Cho","year":"2008","unstructured":"Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14(5):1310\u20131316","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3209_CR26","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1158\/1078-0432.CCR-11-2938","volume":"18","author":"WC Zamboni","year":"2012","unstructured":"Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R, Nel A, Panaro NJ, Grodzinski P (2012) Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 18(12):3229\u20133241","journal-title":"Clin Cancer Res"},{"key":"3209_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejpb.2017.03.013","volume":"115","author":"X Zang","year":"2017","unstructured":"Zang X, Zhao X, Hu H, Qiao M, Deng Y, Chen D (2017) Nanoparticles for tumor immunotherapy. Eur J Pharm Biopharm 115:243\u2013256","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"3209_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bbmt.2005.09.003","volume":"12","author":"WK Decker","year":"2006","unstructured":"Decker WK, Xing D, Shpall EJ (2006) Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transplant 12(2):113\u2013125","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"3209_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1413","volume":"4","author":"MJ Bevan","year":"2004","unstructured":"Bevan MJ (2004) Helping the CD8(+) T-cell response. Nat Rev Immunol 4(8):595\u2013602","journal-title":"Nat Rev Immunol"},{"issue":"21","key":"3209_CR30","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1158\/0008-5472.CAN-10-1322","volume":"70","author":"R Bos","year":"2010","unstructured":"Bos R, Sherman LA (2010) CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 70(21):8368\u20138377","journal-title":"Cancer Res"},{"issue":"7272","key":"3209_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nature08511","volume":"462","author":"Y Nakanishi","year":"2009","unstructured":"Nakanishi Y, Lu B, Gerard C, Iwasaki A (2009) CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462(7272):510\u2013513","journal-title":"Nature"},{"issue":"7","key":"3209_CR32","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.4049\/jimmunol.1401571","volume":"195","author":"Z Zhu","year":"2015","unstructured":"Zhu Z, Cuss SM, Singh V et al (2015) CD4+ T cell help selectively enhances high-avidity tumor antigen-specific CD8+ T cells. J Immunol 195(7):3482\u20133489","journal-title":"J Immunol"},{"issue":"5","key":"3209_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.vaccine.2010.11.036","volume":"29","author":"DA Wick","year":"2011","unstructured":"Wick DA, Martin SD, Nelson BH, Webb JR (2011) Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine 29(5):984\u2013993","journal-title":"Vaccine"},{"key":"3209_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jconrel.2014.07.040","volume":"192","author":"LJ Cruz","year":"2014","unstructured":"Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, L\u00f6wik CW, Ossendorp F (2014) Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release 192:209\u2013218","journal-title":"J Control Release"},{"issue":"7","key":"3209_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nri2569","volume":"9","author":"TB Geijtenbeek","year":"2009","unstructured":"Geijtenbeek TB, Gringhuis SI (2009) Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9(7):465\u2013479","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3209_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ (2009) Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol Rev 229(1):152\u2013172","journal-title":"Immunol Rev"},{"issue":"14","key":"3209_CR37","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1016\/j.biomaterials.2011.01.067","volume":"32","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, Reinhold B, Keskin DB, Reinherz EL, Sasada T (2011) Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 32(14):3666\u20133678","journal-title":"Biomaterials"},{"issue":"5","key":"3209_CR38","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/eji.200737984","volume":"38","author":"V Manolova","year":"2008","unstructured":"Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF (2008) Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38(5):1404\u20131413","journal-title":"Eur J Immunol"},{"issue":"50","key":"3209_CR39","doi-asserted-by":"publisher","first-page":"7292","DOI":"10.1016\/j.vaccine.2012.09.036","volume":"30","author":"D Raghuwanshi","year":"2012","unstructured":"Raghuwanshi D, Mishra V, Suresh MR, Kaur K (2012) A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. Vaccine 30(50):7292\u20137299","journal-title":"Vaccine"},{"issue":"1","key":"3209_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.smim.2011.01.001","volume":"23","author":"PJ Tacken","year":"2011","unstructured":"Tacken PJ, Figdor CG (2011) Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol 23(1):12\u201320","journal-title":"Semin Immunol"},{"issue":"1","key":"3209_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.coi.2007.12.002","volume":"20","author":"S Burgdorf","year":"2008","unstructured":"Burgdorf S, Kurts C (2008) Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol 20(1):89\u201395","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"3209_CR42","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/nmat4718","volume":"15","author":"KM Tsoi","year":"2016","unstructured":"Tsoi KM, MacParland SA, Ma XZ, Spetzler VN, Echeverri J, Ouyang B, Fadel SM, Sykes EA, Goldaracena N, Kaths JM, Conneely JB, Alman BA, Selzner M, Ostrowski MA, Adeyi OA, Zilman A, McGilvray ID, Chan WC (2016) Mechanism of hard-nanomaterial clearance by the liver. Nat Mater 15(11):1212\u20131221","journal-title":"Nat Mater"},{"issue":"2","key":"3209_CR43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161(2):505\u2013522","journal-title":"J Control Release"},{"issue":"9","key":"3209_CR44","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nnano.2017.113","volume":"12","author":"Y Min","year":"2017","unstructured":"Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ (2017) Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol 12(9):877\u2013882","journal-title":"Nat Nanotechnol"},{"issue":"19","key":"3209_CR45","doi-asserted-by":"publisher","first-page":"11969","DOI":"10.1021\/acsami.6b01135","volume":"8","author":"L Liu","year":"2016","unstructured":"Liu L, Cao F, Liu X, Wang H, Zhang C, Sun H, Wang C, Leng X, Song C, Kong D, Ma G (2016) Hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticles as a nanovaccine induce robust humoral and cellular immune responses. ACS Appl Mater Interfaces 8(19):11969\u201311979","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"3209_CR46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1021\/acs.molpharmaceut.8b00700","volume":"16","author":"ST Jahan","year":"2019","unstructured":"Jahan ST, Sadat SMA, Yarahmadi M, Haddadi A (2019) Potentiating antigen specific immune response by targeted delivery of the PLGA-based model cancer vaccine. Mol Pharm 16(2):498\u2013509","journal-title":"Mol Pharm"},{"key":"3209_CR47","first-page":"1","volume":"CII","author":"G H\u00e4nel","year":"2021","unstructured":"H\u00e4nel G, Angerer C, Petry K, Lichtenegger FS, Subklewe M (2021) Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens. Cancer Immunol Immunother CII:1\u201314","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03209-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03209-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03209-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T04:10:23Z","timestamp":1666584623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03209-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3209"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03209-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"15 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Army Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that there are no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}